Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Suven gets patent for Alzheimer's compound

This article was originally published in Scrip

Executive Summary

The Indian biopharmaceutical company Suven Life Sciences has been granted patents on its clinical candidate (SUVN-502) for Alzheimer's disease in several countries. These include India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe and the patent is valid till June 2023, the company informed the Bombay Stock Exchange. SUVN-502 is a potent, highly selective, brain penetrant and orally active antagonist at a non-peripheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition such as attention deficient hyperactivity, Parkinson's disease and schizophrenia. The compound has completed Phase I single-ascending and multiple-ascending studies in Switzerland and has demonstrated safety at all doses, with potential as a once-daily treatment. Phase II proof-of-concept studies are expected next year. Suven has also claimed that some companies have initiated the process of due diligence for potential partnerships for SUVN-502.

You may also be interested in...



More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

Indian Marketers Co-Accountable For Quality Lapses

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005016

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel